The ASH Choosing Wisely® Campaign: five hematologic tests and treatments to question

Lisa K. Hicks, Harriet Bering, Kenneth R. Carson, Judith Kleinerman, Vishal Kukreti, Alice Ma, Brigitta U. Mueller, Sarah H. O'Brien, Marcelo Pasquini, Ravindra Sarode, Lawrence Solberg Jr., Adam E. Haynes and Mark A. Crowther
This article has an Erratum 123(21):3364


Choosing Wisely® is a medical stewardship and quality improvement initiative led by the American Board of Internal Medicine Foundation in collaboration with leading medical societies in the United States. The American Society of Hematology (ASH) is an active participant in the Choosing Wisely® project. Using an iterative process and an evidence-based method ASH has identified five tests and treatments that in some circumstances are not well supported by evidence and which in certain cases involve a risk of adverse events and financial costs, with low likelihood of benefit. The ASH Choosing Wisely® recommendations focus on avoiding liberal red blood cell transfusion, avoiding thrombophilia testing in adults in the setting of transient major thrombosis risk factors, avoiding IVC filter usage except in specified circumstances, avoiding the use of plasma or prothrombin complex concentrate (PCC) in the non-emergent reversal of vitamin K antagonists, and limiting routine CT surveillance following curative-intent treatment of non-Hodgkin lymphoma. We recommend that clinicians carefully consider anticipated benefits of the identified tests and treatments before performing them.

  • Submitted July 30, 2013.
  • Accepted September 9, 2013.